Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Dmv-Fonterra Excipients Technology Gmbh, , Glaxo Group Limited patent solves the following problem:

In the field of inhalation therapy, it is generally desirable to use therapeutic molecules having a particle size (ie, diameter) in the range of 1 to 10 m. carrier molecule or excipients, such as lactose, canine therapeutic preparation also includes significantly larger diameter particles (for example, 100 to 150 m) which are not normally penetrate into the upper respiratory tract to the same degree as the active ingredient. In general, it is better to use a smaller particle size for the lactose or a lactose blend having a defined ratio of coarse and fine lactose.

Our analysis of this patent is as follows:

Dmv-Fonterra Excipients Technology Gmbh, , Glaxo Group Limited’s patent US 9365905 B2 deals with Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom.
A process for forming lactose suitable for use in a pharmaceutical formulation comprises providing a plurality of lactose particles containing no more than 10% w / w of lactose particles with a number average the particle size of about 70 microns or less; stands the plurality of lactose particles to yield a plurality of milled lactose particles with an average particle size, (D50), from 50 micron to 100 micron; and classifying the plurality of milled lactose particles at least two pieces consisting of a fine particle and a coarse particle in which the fine particle has an average particle size, (D50), from 3 microns to 50 microns, and the coarse particle has an average particle size, (D50), from 40 micron to 250 micron.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Composition for flexible membranes

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Sika Technology Ag patent solves the following problem:

Our analysis of this patent is as follows:

Sika Technology Ag’s patent US 9309400 B2 deals with Composition for flexible membranes.
A composition including a styrene block copolymer, a polar-modified styrene block copolymer, plant fibers and a polyolefin strong at 25 C., and the molten body, especially the membranes, made from such compositions.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Separation of screen usage for complex language input

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Z124 patent solves the following problem:

A substantial number of handheld devices Computing, such as cellular phones, tablets, and E-Readers, make use of a touch screen display will not only save the display information to the user, but also to take inputs from the user's command interface. While touch screen display can increase the configurability of the handheld device and to provide a wide variety of user interface options, this flexibility often comes at a price. The two use the touch screen to provide for and receive user commands, while flexible for the user, in order to obfuscate the display, and cause visual clutter, thus leading to user frustration and loss of yield.

Our analysis of this patent is as follows:

Z124’s patent US 9104366 B2 deals with Separation of screen usage for complex language input.
These methods and devices including providing a device having at least a first screen and a secondary screen; receiving a first input, where the first input includes an input language on the first screen; processing the first input to estimate a character based on previous input; to display the estimated character (s); and to exercise a choice, where the selection includes a choice of traits selected from the estimated character (s).

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Multi-operating system

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Z124 patent solves the following problem:

This relates generally to the field of mobile environments Computing, and especially to support many user environment through the use of multiple operating systems on a single mobile computing device.

Our analysis of this patent is as follows:

Z124’s patent US 8898443 B2 deals with Multi-operating system.
A mobile computing devices with a mobile operating systems and desktop operating systems running simultaneously and independently on a shared grain without virtualization. The mobile operating system provides a user experience for mobile computing devices that case the mobile environment. The desktop operating system provides a complete desktop user experience when the mobile computing device is docked to a secondary terminal around. The mobile computing device may be a smartphone running the Android mobile OS and a complete desktop Linux distribution on a modified Android kernel.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Orientation arbitration

File for Quick & Easy Patent Protection with PowerPatent.

The Z124 patent solves the following problem:

A substantial number of handheld devices Computing, such as cellular phones, tablets, and E-Readers, make use of a touch screen display will not only save the display information to the user, but also to take inputs from the user's command interface. While touch screen display can increase the configurability of the handheld device and to provide a wide variety of user interface options, this flexibility often comes at a price. The two use the touch screen to provide for and receive user commands, while flexible for the user, in order to obfuscate the display, and cause visual clutter, thus leading to user frustration and loss of yield.

Our analysis of this patent is as follows:

Z124’s patent US 8868135 B2 deals with Orientation arbitration.
Methods and devices for Configuring and displaying individual screens display a multi-display device. Particularly, the method includes determining and presenting the display orientation on each display independent of other performances. The creative approach and become a picture display orientation on a display screen while simultaneously presenting a landscape display orientation on another display screen. Show the orientation will be based on the desire of the user and / or requirements for a host application. The rotation of the multi-display device, each screen display can be configured to maintain its orientation or can be configured to allow the display orientation to change, for example from the picture to the scene orientation. The display orientation characteristics for each display screen can be user selectable.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Aminopyrimidines as Syk inhibitors

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Merck Sharp & Dohme Corp., , Merck Canada Inc. patent solves the following problem:

Spleen Tyrosine Kinase (SYK) is a protein tyrosine kinase described as a key mediator of immunoreceptor signaling a host of inflammatory cells including mast cells, B-cells, macrophages and neutrophils. These immunoreceptors, including Fc receptor and the B-cell receptor, is important for allergic diseases, and antibody-mediated autoimmune diseases and thus pharmacologically interfering SYK conceivably treat these diseases.

Our analysis of this patent is as follows:

Merck Sharp & Dohme Corp., , Merck Canada Inc.’s patent US 8735417 B2 deals with Aminopyrimidines as Syk inhibitors.
The present invention provides new pyrimidine amines of formula (I), which is a strong inhibitor of spleen tyrosine kinase, and is useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Prebiotic oligosaccharides

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The The Regents Of The University Of California, , Dsm Food Specialties Usa Inc. patent solves the following problem:

Galacto-oligosaccharides (gos) the non-digestible carbohydrates and versatile food mixture to possess prebiotic properties (Angus, F., Smart, S. and Shortt, C. 2005. Probiotic Dairy Products ed. Tamine A. pp. 120 137. Oxford: Blackwell Publishing). Moreover, many other health benefits report for these oligosaccharides including: development of defecation, stimulation of mineral absorption, elimination of ammonium, prevention colon cancer, as well as to protect against certain pathogenic bacteria infection (Hopkins, MJ and Macfarlane, GT 2003 around Appl Microbiol 69, 1920-1927; Shoaf, K., GL Mulvey, GD Armstrong and RW Hutkins 2006 infect Immun 74 :. 6920-8; Macfarlane, GT, horse H. Macfarlane S. 2008 Journal of Applied Microbiology 104, 305-44).

Our analysis of this patent is as follows:

The Regents Of The University Of California, , Dsm Food Specialties Usa Inc.’s patent US 8425930 B2 deals with Prebiotic oligosaccharides.
The present invention provides galacto-oligosaccharide composition that preferentially stimulate the growth of certain strains of Bifidobacterium species.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Flexible thermoplastic composition with improved resistance to the effect of oils, and use of such a composition

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Arkema France patent solves the following problem:

Described in the document WO 02/28959, in the name of the Applicant, is a grafted copolymer having polyamide blocks of a polyolefin backbone selected from ethylene / maleic anhydride and ethylene / alkyl (meth) acrylate / maleic anhydride copolymers, forming a co -Continuous nanostructured combination; It gives this copolymer exceptional thermomechanical properties, retained when redispersing this graft copolymer in flexible polyolefins such as flexible ethylene copolymers.

Our analysis of this patent is as follows:

Arkema France’s patent US 8227543 B2 deals with Flexible thermoplastic composition with improved resistance to the effect of oils, and use of such a composition.
The invention relates to a flexible thermoplastic compositions resistant to the aging effects of the oil, said composition comprising a grafted copolymer containing polyamide blocks and consists of a polyolefin backbone and at least one polyamide graft. According to the invention, the grafts were incorporated into the core of the residues of an unsaturated monomer (X) is a function of the reaction of a polyamide that consists of a wet end or a carboxylic acid end; the residues of the unsaturated monomer (X) is attached to the backbone by grafting or copolymerization from its double bond; and the composition contains between 40 to 90 wt% of polyolefin core containing unsaturated monomer (X); between 5 to 40 wt% of polyamide maayom; and between 5 to 40% of at least one polymer selected from a saponified ethylene / vinyl acetate copolymer and a polyamide.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Use of dietary fibres against muscle wasting

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The N.V. Nutricia patent solves the following problem:

Severe weight loss and in particular muscle wasting is a serious phenomenon that occurs on a broad scale in patients suffering from diseases, disorders and trauma. Muscle destruction (abbreviated as MW) in chronic pain described as a voluntary loss of weight of more than 5% body within one month. If loss of lean body mass (abbreviated as LBM) occurs at a more gradual rate, but during a longer period, the inventors refer to chronic muscle wasting (abbreviated as CMW), particularly if more than 10% of body weight lost in a period of 6 months. MW is typically observed during recovery of trauma or surgery. CMW typically observed in severe diseases such as cancer, AIDS, COPD, diabetes mellitus, and heart failure. The rate of muscle destruction associated with increased morbidity and mortality. The cause of muscle wasting as a result of a disease believed to be multifactorial. Muscle destruction can also be caused by malnourishment, in particular protein-energy malnourishment. In particular the latter type of malnourishment can be treated or prevented by providing extra protein or energy proposed in EP 0721742.

Our analysis of this patent is as follows:

N.V. Nutricia’s patent US 8143235 B2 deals with Use of dietary fibres against muscle wasting.
A nutritional composition containing food fibers useful for the treatment of muscle destruction, if the food fiber comprising at least 30 wt. % Galacto-oligosaccharides or other oligosaccharides topped anhydropyranose units, and has a chain length of 3-10 units. composition may further include other oligo- or polysaccharides, especially polysaccharides which have a majority of anhydrofuranose units.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Glaxo Group Limited patent solves the following problem:

Phosphodiesterase 4 inhibitor (PDE4 inhibitor) may be useful in treating and / or Branch Tomato in a variety of diseases / conditions, especially inflammatory and / or allergic diseases, in mammals such as humans, for example -ingnan: chronic obstructive pulmonary disease (COPD) (eg chronic bronchitis and / or emphysema), asthma, rhinitis (eg allergic or non-allergic rhinitis), rheumatoid arthritis, atopic dermatitis, psoriasis, urticaria, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, septic shock, inflammatory bowel disease (eg ulcerative colitis and / or Crohn's disease), reperfusion injury of the myocardium and / or brain, chronic glomerulonephritis, endotoxic shock, or adult respiratory distress syndrome, in mammals such as humans .

Our analysis of this patent is as follows:

Glaxo Group Limited’s patent US 8003663 B2 deals with Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors.
invention provides N – {[1,6-diethyl-4- (tetrahydro-2H-pyran-4-ylamino) -1H-pyrazolo [3,4-b] pyridin-5-YL] methyl} -4 – ({8 – [ (2-hydroxyethyl) (methyl) amino] octanoyl} amino) benzamide, whose formula is or a salt thereof, as the monohydrochloride salt thereof. the invention also provides the use of the compound or salt as inhibitor of phosphodiesterase type IV (PDE4) and / or for the treatment and / or Branch Tomato inflammatory and / or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma , or rhinitis (eg allergic and / or non-allergic rhinitis).

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.